Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants

Regulatory Toxicology and Pharmacology

Volumn 65, Issue 1, 2013, Pages 126-134

  Valcke, Mathieu ^a,b   Krishnan, Kannan ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

CYP2E1 1A2; First pass effect; Human kinetic adjustment factor; Interindividual variability; Monte Carlo simulations; Oral exposure; Risk assessment; Steady state toxicokinetics

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; TOXIN;

ADULT; ARTERIAL BLOOD; ARTICLE; BLOOD LEVEL; CANCER RISK; CHILD; CONTROLLED STUDY; ENZYME SUBSTRATE; FIRST PASS EFFECT; HUMAN; HUMAN KINETIC ADJUSTMENT FACTOR; INFANT; LIVER METABOLISM; METABOLIC PARAMETERS; METABOLIC RATE; MONTE CARLO METHOD; NEWBORN; PARTITION COEFFICIENT; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; STEADY STATE; TODDLER; TOXICOKINETICS;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; ENVIRONMENTAL EXPOSURE; HUMANS; INFANT; INFANT, NEWBORN; LIVER; MONTE CARLO METHOD; PHARMACOKINETICS; RISK ASSESSMENT;

EID: 84871450542     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.11.006     Document Type: Article

References (70)

1. Abuasal B.S., Bolger M.B., Walker D.K., Kaddoumi A. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrates. Mol. Pharm. 2012, 5:492-504.
2. Andersen M.E. A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. Toxicol. Appl. Pharmacol. 1981, 60:509-526.
3. Aylward L.L., Kirman C.R., Blount B.C., Hays S.M. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) - application of steady-state PBPK model solutions. Regul. Toxicol. Pharmacol. 2010, 58:33-44.
4. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlile D.J., Edwards R.J., et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro-data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8:33-45.
5. Barter Z.E., Chowdry J.E., Harlow J.R., Snawder J.E., Lipscomb J.C., Rostami-Hodjegan A. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab. Dispos. 2008, 36:2405-2409.
6. Beck B.D., Mattuck R.L., Bowers T.S. Adult-child differences in the intraspecies uncertainty factor: a case study using lead. Human Ecol. Risk Assess. 2002, 8:877-884.
7. Bogen K.T. Pharmacokinetics for regulatory risk analysis: the case of trichloroethylene. Regul. Toxicol. Pharmacol. 1988, 8:447-466.
8. Bogen K.T., Gold L.S. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points. Regul. Toxicol. Pharmacol. 1997, 25:26-42.
9. Bogen K.T., Hall L.C. Pharmacokinetics for regulatory risk analysis: the case of 1,1,1-trichloroethane (methyl chloroform). Regul. Toxicol. Pharmacol. 1989, 10:26-50.
10. Bogen K.T., McKone T.E. Linking indoor air and pharmacokinetic models to assess tetrachloroethylene risk. Risk Anal. 1988, 8:509-520.
11. Cheng X., Klaassen C.D. Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys. Drug Metab. Dispos. 2009, 37:2178-2185.
12. Chiu W.A., White P. Steady-state solutions to PBPK models and their applications to risk assessment I: route-to-route extrapolation of volatile chemicals. Risk Anal. 2006, 26:769-780.
13. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 2004, 79:381-393.
14. Clewell H.J., Teeguarden J., McDonald T., Sarangapani R., Lawrence G., Covington T., Gentry R., Shipp A. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 2002, 32:329-389.
15. Csanady G.A., Filser J.G. The relevance of physical activity for the kinetics of inhaled gaseous substances. Arch. Toxicol. 2001, 74:663-672.
16. Delic J.I., Lilly P.D., MacDonald A.J., Loizou G.D. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. Regul. Toxicol. Pharmacol. 2000, 32:144-155.
17. DeWoskin R.S., Thompson C.M. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul. Toxicol. Pharmacol. 2008, 51:66-86.
18. Dorne J.L., Renwick A.G. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 2005, 86:20-26.
19. Dorne J.L., Walton K., Renwick A.G. Uncertainty factors for chemical risk assessment: human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem. Toxicol. 2001, 39:681-696.
20. Dourson M.L., Felter S.P., Robinson D. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 1996, 24:108-120.
21. Edwards D.J., Stoeckel K. The pharmacokinetics of new oral cephalosporins in children. Chemotherapy 1992, 38(s2):2-9.
22. Fanta S., Jönsson S., Backman J.T., Karlsson M.O., Hoppu K. Developmental pharmacokinetics of ciclosporin - a population pharmacokinetic study in paediatric renal transplant candidates. Br. J. Clin. Pharmacol. 2007, 64:772-784.
23. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker Inc., New York NY. second ed.
24. Gillette, J.R., 1980. Pharmacokinetic factors governing the steady-state concentrations of foreign chemicals and their metabolites. In: Evered, D., Lawrenson, G. (Eds.), Environmental Chemicals, Enzyme Function and Human Disease. Ciba Foundation Symposium 76, Glendale, pp. 191-217.
25. Ginsberg G., Smolenski S., Neafsey P., Hattis D., Walker K., Guyton K.Z., Johns D.O., Sonawane B. The influence of genetic polymorphism on population variability in six xenobiotic-metabolizing enzymes. J. Toxicol. Environ. Health B 2009, 12:307-333.
26. Ginsberg G., Foos B.P., Firestone M.P. Review and analysis of inhalation dosimetry methods for application to children's risk assessment. J. Toxicol. Environ. Health A 2005, 68:573-615.
27. Haddad S., Beliveau M., Tardif R., Krishnan K. A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. Toxicol. Sci. 2001, 63:125-131.
28. Haddad S., Tardif G.C., Tardif R. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes. J. Toxicol. Environ. Health A 2006, 69:2095-2136.
29. Hassan M., Ljungman P., Bolme P., Ringden O., Syruckova Z., Stary J., Wallin I., Kallberg N. Busulfan bioavailability. Blood 1994, 84:2144-2150.
30. Heikkinen A.T., Baneyx G., Caruso A., Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus™. Eur. J. Pharm. Sci. 2012, 47:375-386.
31. Hellreigel E., Bjornsson T.J., Hauck W.W. Interpatient variability in bioavailability is related to the extent of absorption: implication for bioavailability ad bioequivalence studies. Clin. Pharmacol. Ther. 1996, 60:601-607.
32. IPCS, 2005. Chemical-Specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability: Guidance Document for the Use of Data in Dose/Concentration-Response Assessment. WHO/IPCS/01.4. International Panel on Chemical Safety, World Health Organisation, Geneva, Switzerland, pp. 1-96.
33. Jacqz-Aigrain E. Pharmacologie du développement. Médecine et biologie du développement, du gène au nouveau-né 2001, 399. Masson, Paris. E. Saliba, S. Hamamah, F. Gold, M. Benhamed (Eds.).
34. Johnson T.N. Modelling approaches to dose estimation in children. Br. J. Clin. Pharmacol. 2005, 59:663-669.
35. Johnsrud E.K., Koukouritaki S.B., Divakaran K., Brunengraber L.L., Hines R.N., McCarver D.G. Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 2003, 307:402-407.
36. Katsura T., Inui K. Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab. Pharmacokin. 2003, 18:1-15.
37. Lacroix D., Sonnier M., Moncion A., Cheron G., Cresteil T. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 1997, 247:625-634.
38. Lindhal A., Sanström R., Ungell A.L., Abrahamsson B., Knotson T.W., Knotson L., Lennernäs H. Jejunal permeability and hepatic extraction of flovastatin in humans. Clin. Pharmacol. Ther. 1996, 60:493-503.
39. Lipscomb J.C., Poet T.S. In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol. Ther. 2008, 118:82-103.
40. Lipscomb J.C., Teuschler L.K., Swartout J., Swan G.E., Snawder J.E. Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol. Mech. Meth. 2003, 13:45-51.
41. Lu Y., Rieth S., Lohitnavy M., Dennison J., El-Masri H., Barton H.A., Bruckner J., Yang R.S. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane. Regul. Toxicol. Pharmacol. 2008, 50:249-260.
42. Maher J.M., Slitt A.L., Cherrington N.J., Cheng X., Klaassen C.D. Tissue distribution and hepatic and renal ontogeny of the multidrugresistance-associated protein (Mrp) family in mice. Drug Metab. Dispos. 2005, 33:947-955.
43. Meek M.E., Renwick A., Ohanian E., Dourson M., Lake B., Naumann B.D., Vu V. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicology 2002, 181-182:115-120.
44. Neafsey P., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J. Toxicol. Environ. Health B 2009, 12:362-388.
45. Nelson W.E. Textbook of Pediatrics 1991, W.B. Sauders Company, New York.
46. Nong A., Krishnan K. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach. Regul. Toxicol. Pharmacol. 2007, 48:93-101.
47. Nong A., McCarver D.G., Hines R.N., Krishnan K. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 2006, 214:78-87.
48. Pelekis M., Gephart L.A., Lerman S.E. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul. Toxicol. Pharmacol. 2001, 33:12-20.
49. Pelekis M., Krewski D., Krishnan K. Physiologically based algebraic expressions for predicting steady-state toxicokinetics of inhaled vapors. Toxicol. Meth. 1997, 7:205-225.
50. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 2003, 33:469-503.
51. Ramsey J.C., Andersen M.E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 1984, 73:159-175.
52. Reitz R.H., Gargas M.L., Andersen M.E., Provan W.M., Green T.L. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. Toxicol. Appl. Pharmacol. 1996, 137:253-267.
53. Renwick A.G., Lazarus N.R. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 1998, 27:3-20.
54. Ronis M.J.J., Lindros K.O., Ingelman-Sundberg M. The CYP2E family. Cytochrome P450 Metabolic and Toxicological Aspects 1996, 211-240. CRC Press, Boca Raton FL. C. Ioannides (Ed.).
55. Rowland M., Tozer T.N. Clinical pharmacokinetics - concepts and applications 1995, Lippincott, Williams and Wilkins, Media, PA. third ed.
56. Sarangapani R., Gentry P.R., Covington T.R., Teeguarden J.G., Clewell H.J. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal. Toxicol. 2003, 15:987-1016.
57. Schiengold M., Schwantes L., Schwartsmann G., Chies J.A., Nardi N.B. Multidrug resistance gene expression during the murine ontogeny. Mech. Ageing Dev. 2001, 122:255-270.
58. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270:414-423.
59. Sonnier M., Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem. 1998, 251:893-898.
60. Statistics Canada, 2003. Canadian Community Health Survey, Cycle 2.1. Available from: (last accessed 01.02.10). http://www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl?Function=getSurvey&SurvId=3226&SurvVer=0&SDDS=3226&InstaId=15282&InstaVer=2&lang=en&db=imdb&adm=8&dis=2.
61. St-Pierre M.V., Stallmach T., Freimoser Grundschober A., Dufour J.F., Serrano M.A., Marin J.J., Sugiyama Y., Meier P.J. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:1505-1516.
62. Strange R.C., Howie A.F., Hume R., Matharoo B., Bell J., Hiley C., Jones P., Beckett G.J. The development expression of alpha-, mu- and pi-class glutathione S-transferases in human liver. Biochim. Biophys. Acta 1989, 99:186-190.
63. Tamura S., Tokunaga Y., Ibuki R., Amidon G.L., Sezaki H., Yamashita S. The site-specific transport and metabolism of tacrolimus in rat small intestine. J. Pharmacol. Exp. Ther. 2003, 306:310-316.
64. Tardif R., Lapare S., Charest-Tardif G., Brodeur J., Krishnan K. Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. Risk Anal. 1995, 15:335-342.
65. Thummel K.E., O'Shea D., Paine M.F., Shen D.S., Kunze K.L., Perkins J.D., Wilkinson G.R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 1996, 59:491-502.
66. US EPA, 2002. A review of the reference dose and reference concentration process. Risk Assessment Forum. EPA/630/P-02/00F. Washington, DC, USA.
67. Valcke M., Krishnan K. Evaluation of the impact of the exposure route on the human kinetic adjustment factor. Regul. Toxicol. Pharmacol. 2011, 59:258-269.
68. Valcke M., Krishnan K. Evaluation of the Impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants. Toxicology 2011, 286:36-47.
69. Valcke M., Krishnan K. Assessing the impact of the duration and intensity of inhalation exposure on the magnitude of the variability of internal dose metrics in children and adults. Inhal. Toxicol. 2011, 23:863-877.
70. Walker K., Hattis D., Russ A., Sonawane B., Ginsberg G. Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences. J. Toxicol. Environ. Health A 2007, 70:2033-2055.